SLU-PP-332 vs Testosterone
Emerging vs FDA Approved
avoid Mechanism-based · 53% Both SLU-PP-332 and Testosterone carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.
Molecular Data
SLU-PP-332 Testosterone
Weight 290.32 Da 288.42 Da (base)
Half-life Under investigation (no human PK data) ~8 days (cypionate)
Chain Non-peptide small molecule —
Type Synthetic ERR agonist Steroid hormone (C19H28O2)
Key Benefits
SLU-PP-332
01 Exercise mimetic effects without physical activity
02 12% weight loss in 28 days
03 70% increased endurance
04 25% enhanced fatty acid oxidation
05 Improved insulin sensitivity
06 Reduced hepatic steatosis
07 Cardiac protection
08 Reversal of age-related mitochondrial dysfunction
Testosterone
01 Restoration of normal testosterone levels in hypogonadal men
02 Increased lean muscle mass and strength
03 Improved bone mineral density and reduced fracture risk
04 Enhanced libido, sexual function, and erectile quality
05 Improved mood, energy, motivation, and cognitive clarity
06 Reduction in body fat percentage, particularly visceral fat
07 Increased red blood cell production and oxygen-carrying capacity
08 Improved insulin sensitivity and metabolic health markers
Dosing Protocols
SLU-PP-332
NO HUMAN DOSE ESTABLISHED (animal studies: 50 mg/kg IP) / Research only - not approved for human use
Standard Metabolic Protocol 50 mg/kg (animal dosing) Twice daily
Acute Exercise Enhancement 50 mg/kg (animal dosing) Single dose 1 hour pre-exercise
Extended Treatment 50 mg/kg (animal dosing) Twice daily for 4-8 weeks
Testosterone
100-200 mg/week (TRT) / 1-2x per week (injectable)
TRT - Standard Replacement 100-200 mg/week 1-2x per week
TRT - Conservative Start 80-100 mg/week 2x per week (40-50 mg per injection)
TRT - Propionate Protocol 25-50 mg every other day Every other day or 3x per week
Performance Enhancement - Moderate 300-500 mg/week 2x per week
Performance Enhancement - Advanced 500-750 mg/week 2-3x per week
Side Effects
SLU-PP-332
Animal studies show favorable safety with no severe effects at therapeutic doses
Well-tolerated in rodents and canines
No liver, kidney, or cardiac toxicity documented
No lean mass loss
Does not suppress hormones or act as stimulant
Minor plasma cholesterol and liver enzyme changes in some studies
Testosterone
Acne and oily skin (increased sebum production via DHT)
Water retention and bloating (estrogen-mediated)
Mild mood changes (irritability, increased assertiveness)
Increased hematocrit and hemoglobin (erythrocytosis)
Testicular atrophy (suppression of LH/FSH from exogenous testosterone)
Injection site pain, redness, or irritation
Increased body hair growth
Mild elevation in blood pressure
Contraindications
NOT FOR HUMAN USE - no approved human dose
No human clinical trials conducted
Potential interaction with diabetes medications
Prostate cancer (active or history of hormone-sensitive prostate cancer)
Breast cancer in males
Polycythemia (hematocrit above 54% at baseline)
Uncontrolled severe heart failure
Untreated severe obstructive sleep apnea
Desire for near-term fertility (without concurrent HCG/FSH)
Pregnancy or potential exposure to pregnant women (Category X)
Hypersensitivity to testosterone or any formulation components
Research Evidence
SLU-PP-332 Testosterone
Status Emerging FDA Approved
References 4 studies 5 studies
Latest 2025 June 2023
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.